Industry reporting detailed how Lilly’s Kelonia acquisition fits a broader “in vivo” genetic medicines strategy, building on prior deals to expand the company’s cell therapy and genetic medicine toolkit. The move is framed as the latest step after Lilly acquired other in vivo-focused companies, each designed around distinct mechanisms to produce therapeutic cells or payloads inside the body. The reports connect Kelonia’s lentiviral in vivo gene placement system to Lilly’s stated ambition to grow beyond its GLP-1 franchises, targeting hematology with a platform that could reduce manufacturing complexity and broaden access compared with ex vivo CAR T. Beyond the business strategy, the deal underscores how large pharma continues shifting toward platform acquisitions to accelerate pipeline buildouts in cell therapy.